A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer
ConclusionThis study met its feasibility endpoints. This novel pragmatic trial approach offers a means of comparing standard of care treatments in a practical and cost-effective manner. The trial will now be expanded to compare rates of FN between the three filgrastim schedules.Trial registrationClinicalTrials.gov: NCT02428114.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Filgrastim | Neulasta | Neupogen | Oral Cancer | Study | Toxicology